Calianno G, Esposito M, Fidanza R, et al. - Researchers analyzed a case series of patients suffering from moderate-to-severe plaque psoriasis, to determine real-life effectiveness as well as safety of ixekizumab in the treatment of genital psoriasis (GenPs). Subcutaneous ixekizumab was provided to adult patients suffering from moderate-to-severe plaque psoriasis involving the genital area. At baseline, after 4, 16 and 24 weeks of treatment, assessment of disease severity, clinical symptoms and quality of life was done. A significant improvement in disease severity, itch and quality of life was shown to be conferred by ixekizumab and it also displayed an acceptable safety profile in a real-life setting in adult patients suffering from GenPs.